CD2 and graft versus host disease: Turning to our CD2-targeted tolerogenic NPs, we have demonstrated disease-protective effects in lupus mice and in GvHD, where the depletion of TGF-β-producing NK cells abolished the NPs’ protective effects (5, 42).